XML 81 R57.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock-Based Compensation - Stock Option Activity (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended
Mar. 31, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award        
Granted, Weighted Average Exercise Price   $ 0.49 $ 2.68  
Share based compensation arrangement by share based payment award options, annual accelerate percentage of options vested   6.25%    
Share based compensation arrangement by share based payment award options, percentage of options vested every year   25.00%    
Stock options        
Share-based Compensation Arrangement by Share-based Payment Award        
Accelerated vesting, number of shares 1,535,578      
Unrecognized compensation cost related to nonvested stock-based compensation   $ 1,000    
Weighted average remaining period over which unrecognized compensation expense will be recognized   2 years 4 months 24 days    
Common Stock Options        
Share-based Compensation Arrangement by Share-based Payment Award        
Options, Outstanding, Beginning Balance   5,202,006    
Granted   1,169,800    
Expired   (588,038)    
Options assumed in connection with Aceragen Acquisition   1,887,860    
Options, Outstanding, Ending Balance   7,671,628   5,202,006
Exercisable, Ending Balance   4,218,823    
Weighted Average Exercise Price, Beginning Balance   $ 8.06    
Granted, Weighted Average Exercise Price   0.49    
Expired, Weighted Average Exercise Price   2.87    
Options assumed in connection with Aceragen Acquisition, Weighted Average Exercise Price   4.15    
Weighted Average Exercise Price, Ending Balance   6.34   $ 8.06
Exercisable, Weighted Average Exercise Price   $ 9.29    
Options assumed in connection with Aceragen acquisition, Weighted Average Remaining Contractual Term   9 years 3 months 18 days    
Outstanding, Ending balance, Weighted Average Remaining Contractual Term   7 years 3 months 18 days   5 years 10 months 24 days
Exercisable Ending Balance, Weighted Average Remaining Contractual Term   5 years 8 months 12 days    
Outstanding, Intrinsic Value, Ending Balance       $ 2,949
Preferred Stock Options        
Share-based Compensation Arrangement by Share-based Payment Award        
Options assumed in connection with Aceragen Acquisition   19,826    
Options, Outstanding, Ending Balance   19,826    
Exercisable, Ending Balance   2,187    
Options assumed in connection with Aceragen Acquisition, Weighted Average Exercise Price   $ 394.82    
Weighted Average Exercise Price, Ending Balance   394.82    
Exercisable, Weighted Average Exercise Price   $ 142.05    
Options assumed in connection with Aceragen acquisition, Weighted Average Remaining Contractual Term   9 years 3 months 18 days    
Outstanding, Ending balance, Weighted Average Remaining Contractual Term   9 years 3 months 18 days    
Exercisable Ending Balance, Weighted Average Remaining Contractual Term   8 years 10 months 24 days